Membranoproliferative glomerulonephritis in a puerperal with Sjögren's syndrome: Rare finding or something else?  by Leal, Rita et al.
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embranoproliferative  glomerulonephritis  in a puerperal
ith Sjögren’s  syndrome:  Rare  ﬁnding  or  something  else?
lomerulonefritis  membranoproliferativa  en  una  puerpéra  con
índrome  de  Sjögren:  hallazgo  raro  o  algo  más?
ear Editor,
e  report on a case of a 35-year-old Caucasian woman with
rimary Sjögren’s Syndrome (pSS) diagnosed by salivary gland
The patient was treated with 1 g methylprednisolone
pulses on three consecutive days and subsequent oral predni-
solone at a dosage of 1 mg/kg/day.
One year has passed and the patient has been weaned offiopsy and IgM  monoclonal gammopathy of undetermined
gniﬁcance (MGUS), treated with hydroxychloroquine 200 mg
steroid therapy maintaining clinical stability. Analytically, the
values of sCr have stabilized at 1.0 mg/dL, with proteinuria of
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paily since she was 22 year-old.
After 24 weeks into her ﬁrst pregnancy, she develo-
ed marked asthenia with muscle pain and arthralgia,
ypertension, oedema and palpable purpura of the lower
mbs. Laboratorial testing revealed an increase in serum
eatinine (sCr) (0.75 → 1.18 mg/dL), anaemia (haemoglobin
b) = 8.6 g/dL), active urinary sediment and nephrotic-range
roteinuria (3.8 g/24 h). She was diagnosed with preeclampsia
ith foetal distress and underwent a caesarean at 29 weeks of
regnancy. One week post-partum the patient was discharged
ome with sCr = 0.84 mg/dL, Hb = 12 g/dL, 24-hour proteinu-
a = 1.4 g and normotensive under nifedipine 30 mg  daily.
Three months post-partum, she was admitted to the emer-
ncy room presenting acute pulmonary oedema requiring
vasive ventilatory support. Pulmonary auscultation showed
ne crackles over both lung bases, she had moderate periphe-
l oedema and after urinary catheterization, oligoanuria was
nﬁrmed.
Laboratory tests revealed sCr = 4.39 mg/dL, K+ = 6.6 mmol/L,
rain natriuretic peptide = 5013 pg/mL, Hb = 8.1 g/dL, platelet
unt = 248x109/L and negative blood cultures. Urinalysis sho-
ed 3+ proteinuria on a dipstick test. On echocardiogram there
ere no signs of endocarditis and she had a ventricular ejec-
on fraction of 50%, renal ultrasound revealed normal kidneys
d chest X-ray showed large bilateral pleural effusion.
Continuous haemodiaﬁltration was initiated and the
atient was admitted to the intensive care unit, until she gai-
ed ventilatory autonomy and suspended haemodiaﬁltration,
eing transferred to the Nephrology Department three days
ter for continued care.
A kidney biopsy was performed revealing type I mem-
ranoproliferative glomerulonephritis with IgM (++), IgG (+)
d C3 (++) deposits, glomerular capillary endotheliosis, focal
d segmental thrombotic microangiopathy, tubulointerstitial
ephritis and injuries of focal and discrete vasculitis. (Fig. 1).
Serologies for human immunodeﬁciency virus, hepatitis B
rus and hepatitis C virus (HCV) were negative, as well as HCV
NA testing. Complement study showed low C4 (C4<0,01) and
ormal C3 (C3=1,36) and high rheumatoid factor (195 IU/mL;
 = ). Cryoglobulins were positive with polyclonal IgG and
onoclonal IgM and kappa light chains.0 mg/24 h (Table 1).
The histological ﬁndings of our patients’ kidney biopsy
vealed distinct injury patterns that could be inserted in
rious clinical pictures: glomerular capillary endotheliosis
d focal and segmental thrombotic microangiopathy were
pected in the context of previous preeclampsia1 while
bulointerstitial nephritis with injuries of vasculitis were
mpatible with pSS.2
Regarding the immune complex mediated MPGN, which
ight have been the cause of acute kidney injury, the dif-
rential diagnosis of its underlying cause was challenging
d included autoimmune diseases, chronic infection and
onoclonal gammopathy. MPGN associated with autoim-
une diseases is rarely seen in patients with SS and we  also
cluded chronic infection. Considering monoclonal gammo-
athies, although the immunoﬂuorescence microscopy on
nal biopsy was not typical, our patient was diagnosed with
M  MGUS.3
A growing number of pathologic renal conditions are
eing attributed to a clonal plasma cell disorder that is less
yeloma-like and more  MGUS-like in terms of its bulk and
roliferative rate and the term monoclonal gammopathy ofFig. 1 – Renal biopsy (methenamine silver stain) 200×.
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Table 1 – Analytical evolution of serum creatinine (sCr), proteinuria (Uprot) and serum albumin (sAlb). W = week;
M = month, W = week.
Before pregnancy 24–29 weeks pregnancy 1 W post-partum 3 M post-partum 6 M on steroids
sCr 0.7 1.18 0.84 4.39 1.0
Uprot 0 3.8 1.4 2.5 0.3
sAlb 4.3 2.9 3.2 3.2 4.1
renal signiﬁcance (MGRS) was proposed to clarify the differen-
ces in respect to therapy.4,5 One of the conditions associated
with MGRS is type II cryoglobulinaemia and there are recent
reviews that show a close association between monoclo-
nal gammopathy, cryoglobulinaemias and SS.6,7 In fact, in
patients with SS and MGUS, mixed cryoglobulinaemia should
always be investigated, especially if the monoclonal band is
IgM k, as in the case we  report.
In retrospect, there was several data favouring the diagno-
sis of cryoglobulinaemia in association with pSS, since our
patient presented with Metlzer’s triad and had laboratory ﬁn-
dings compatible with this pathology.8
In summary, our patient had a MGRS associated with type II
cryoglobulinaemia, presenting with MPGN, superimposed on
SS.
Regarding treatment there are still many  doubts about the
best approach. Our patient had several poor prognostic indi-
cators: a severe form of pSS and type II cryoglobulinaemia,
both related to a higher propensity to develop a lymphopro-
liferative disorder, and MGUS, nowadays considered as a key
marker of pSS activity.9,6,10 Considering this data, she could
be a candidate for aggressive therapy with biological agents
against B-cells.
For now, and after suspending steroid treatment, our
patient has normal kidney function without signiﬁcant protei-
nuria or complaints. Our approach is to maintain integrated
inter-department follow up and in the future, rituximab will
be present as a therapeutic option.
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